Celcuity

Celcuity R&D per Employee

The R&D Spending per Employee of Celcuity (CELC) as of Sep 25, 2026 is 935,451.61 USD. In the previous year, R&D Spending per Employee was 672,278.90 USD — a change of 39.15% (higher).

R&D per Employee

935,451.61USD

YoY

39.15%

Last updated:

R&D Spending per Employee of Celcuity is 2026 935,451.61 USD. R&D Spending per Employee of Celcuity was 2025 672,278.90 USD. It decreases by 39.15% higher compared to the previous year.

The Celcuity R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
40,812.87 USD
Jan 1, 2019
40,447.15 USD
Jan 1, 2020
49,571.11 USD
Jan 1, 2021
166,180.68 USD
Jan 1, 2022
227,674.50 USD
Jan 1, 2023
390,929.07 USD
Jan 1, 2024
672,278.90 USD
Jan 1, 2025
935,451.61 USD
The Celcuity R&D per Employee history
YEARR&D per EmployeeYoY
935,451.61USD+39.15%
672,278.90USD+71.97%
390,929.07USD+71.71%
227,674.50USD+37.00%
166,180.68USD+235.24%
49,571.11USD+22.56%
40,447.15USD-0.90%
40,812.87USD+27.02%
32,131.79USD+62.51%
19,772.66USD+52.35%
12,978.83USD—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

R&D Spending per Employee of Celcuity is 935,451.61 USD in 2026.

R&D Spending per Employee of Celcuity changed from 672,278.90 USD to 935,451.61 USD, representing a 39.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Celcuity since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Celcuity historically and in real time.

Access this data via the Eulerpool API

Workforce — Celcuity

All Key Metrics — Celcuity